申请人:Celgene Corporation
公开号:US06326388B1
公开(公告)日:2001-12-04
Substituted 1,3,4-oxadiazole compounds reduce the levels of TNF&agr; in a mammal. Typical embodiments are 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(1,3,4-oxadiazol-2-yl)ethyl]-5-methylisoindoline-1,3-dione and 2-[1-(3-ethoxy-4-methoxyphenyl)-2-(1,3,4-oxadiazol-2-yl)ethyl]isoindoline-1,3-dione.
替代了1,3,4-噁二唑化合物可以降低哺乳动物体内TNF&agr;的水平。典型的实施方式是2-[1-(3-环戊氧基-4-甲氧基苯基)-2-(1,3,4-噁二唑-2-基)乙基]-5-甲基异吲哚啉-1,3-二酮和2-[1-(3-乙氧基-4-甲氧基苯基)-2-(1,3,4-噁二唑-2-基)乙基]异吲哚啉-1,3-二酮。